Anthropic's artificial intelligence model Claude is showing promising results in cancer research and drug development by significantly reducing paperwork and improving experimental treatments. Early collaborations with six organizations have demonstrated Claude's potential to speed up the drug development process, including cancer therapies, food allergy treatments, and regulatory document preparation.
- Claude helped redesign genetic instructions for CAR T-cell therapy, improving its efficiency against solid tumors.
- AI-assisted projects produced molecules binding targets more than 10 times stronger than original versions.
- Claude cut regulatory document review time by 89%, from over 25 hours to under 3 hours.
- Early-stage clinical trial planning improved through AI analysis of proprietary data.
- Anthropic plans to expand AI use in drug development and clinical trials to reduce costs and accelerate research.
How is Claude AI improving cancer research?
Claude has been used by Generate Biomedicines to redesign part of the genetic instructions for CAR T-cell therapy, a treatment traditionally used for blood cancers. The AI proposed new designs that were about 70% shorter and performed better in lab tests. These redesigned cells produced roughly 10 times more receptors to recognize cancer cells, killed tumor cells more efficiently, and remained active longer. This advancement could help adapt CAR T-cell therapy to treat solid tumors, although further testing in humans is needed.
What role does Claude play in developing treatments for food allergies and rare diseases?
Divergence Labs used Claude to develop potential treatments for food allergies, while BigHat Biosciences combined AI with automated lab testing to improve experimental molecules. Over 10 weeks, the team produced and tested about 1,010 molecule variants, with the best binding their targets more than 10 times as tightly as the originals. Additionally, Anthropic acquired Mithril Medicine, which used Claude to coordinate experiments for rare muscular dystrophy treatments, achieving promising results in mice within 18 months.
How does Claude reduce paperwork and speed up regulatory processes?
At Enveda, manufacturing chemists spent up to 75% of their time on paperwork. Anthropic connected Claude to manufacturing documents, allowing the AI to flag potential issues. In a test of 1,061 pages, Claude identified all 11 issues found by humans and flagged 7 more, reducing review time by 89%. Claude also drafted regulatory documents much faster—one took 4 hours compared to about 3 months traditionally—with minimal errors found by human reviewers.
Can Claude improve clinical trial planning?
Anthropic is collaborating with pharmaceutical company Bristol Myers Squibb to use Claude for assessing early-stage drug plans and estimating trial success likelihood. Claude analyzes proprietary data to create clinical study plans and weigh chances of success. Although still early, this partnership aims to expand in 2027 to improve clinical trial outcomes.
What are the future plans for Claude in drug development?
Anthropic is establishing a new company, Pleiades, with The Column Group to manage multiple drug development programs using Claude, aiming to reduce research and administrative costs. The company also launched Claude Science, an AI workbench for researchers, offering credits and access to powerful models for biological research. While most research remains preclinical, Anthropic plans to advance programs into clinical trials, hoping to accelerate medicine discovery and treatment options.
Frequently Asked Questions
Q: What is CAR T-cell therapy and how is Claude improving it?
A: CAR T-cell therapy is a treatment that modifies immune cells to attack cancer. Claude helped redesign the genetic instructions to make these cells more effective against solid tumors by increasing receptor production and tumor-killing ability.
Q: How much has Claude reduced the time for regulatory document review?
A: Claude reduced human review time by 89%, cutting it from more than 25 hours to less than 3 hours while identifying all previously found issues and additional ones.
Q: Are Claude’s improvements already tested in humans?
A: Most of Claude’s work is still at the preclinical stage, with experimental treatments largely untested in humans. Further research and clinical trials are needed to confirm effectiveness.
Q: What diseases is Anthropic targeting with Claude?
A: Anthropic is targeting cancer, food allergies, rare childhood diseases, and muscular dystrophy, among others, aiming to develop new treatments using AI-assisted drug discovery.
Drug development is complex and costly, with many candidates failing in testing. While Claude shows promise in speeding up research and reducing costs, it has yet to prove it can deliver approved medicines faster or cure more patients. Nonetheless, these early results highlight AI’s growing role in transforming medicine.
